Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
718 (USA) · Dr. Nolan
consented 2012-09-19
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-10-05 (study day 17.0); relationship: PROBABLE
severe
assessed
Severe APPLICATION SITE IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-10-05 (study day 17.0); relationship: PROBABLE
moderate
assessed
Moderate CONFUSIONAL STATE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-10-05 (study day 17.0); relationship: POSSIBLE
Data queries
No data queries.